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Human antibody responses against 
non-covalently cell wall-bound 
Staphylococcus aureus proteins
Francisco Romero Pastrana1, Jolanda Neef1, Dennis G. A. M. Koedijk1, Douwe de Graaf1,  
José Duipmans2, Marcel F. Jonkman2, Susanne Engelmann3,4, Jan Maarten van Dijl1 &  
Girbe Buist1
Human antibody responses to pathogens, like Staphylococcus aureus, are important indicators for 
in vivo expression and immunogenicity of particular bacterial components. Accordingly, comparing 
the antibody responses to S. aureus components may serve to predict their potential applicability as 
antigens for vaccination. The present study was aimed at assessing immunoglobulin G (IgG) responses 
elicited by non-covalently cell surface-bound proteins of S. aureus, which thus far received relatively 
little attention. To this end, we applied plasma samples from patients with the genetic blistering disease 
epidermolysis bullosa (EB) and healthy S. aureus carriers. Of note, wounds of EB patients are highly 
colonized with S. aureus and accordingly these patients are more seriously exposed to staphylococcal 
antigens than healthy individuals. Ten non-covalently cell surface-bound proteins of S. aureus, namely 
Atl, Eap, Efb, EMP, IsaA, LukG, LukH, SA0710, Sle1 and SsaA2, were selected by bioinformatics and 
biochemical approaches. These antigens were recombinantly expressed, purified and tested for specific 
IgG responses using human plasma. We show that high exposure of EB patients to S. aureus is mirrored 
by elevated IgG levels against all tested non-covalently cell wall-bound staphylococcal antigens. This 
implies that these S. aureus cell surface proteins are prime targets for the human immune system.
Staphylococcus aureus is a Gram-positive bacterial pathogen that colonizes about one third of the healthy human 
population1. The pathology caused by S. aureus may range from mild skin infections to life-threatening bacter-
emia. Current treatment of S. aureus infections relies on antibiotics, but the emergence of highly drug-resistant 
lineages2 has reignited the interest in alternative treatment options, including passive and active immunization3–7.
Surface-exposed and secreted proteins of S. aureus play pivotal roles in the colonization and subversion of 
the human host8. Accordingly, such proteins have been considered as possible antigens for vaccination against S. 
aureus infections9,10. However, the previous efforts to develop a vaccine against S. aureus have met with little suc-
cess, as exemplified by trials based on capsular polysaccharides or important virulence factors, such as fibronectin 
binding protein (FnBP), collagen binding protein (CnBP), or clumping factor A (ClfA)5,9,11. Most likely, this 
relates to the broad spectrum of virulence and immune evasion factors that S. aureus employs to thrive and 
survive in the human host. Therefore, it has been suggested that potentially successful vaccines need to address 
multiple staphylococcal virulence factors and defense mechanisms5.
The S. aureus genome encodes about 2700 proteins, from which about 120 have been observed more than once 
in the extracellular and cell surface proteomes10,12,13. Since the pioneering experiments published by Etz et al. and 
Vytvytska et al. in 200214,15, diverse immunological and proteomics-based studies have addressed the antibody 
responses against S. aureus9,16. In these studies the antigenicity of non-covalently cell wall-associated proteins 
received relatively little attention. These non-covalently cell wall-associated proteins include proteins with specific 
cell wall-binding domains, ‘secretable expanded repertoire adhesive molecules’ (SERAMs) and typical cytoplas-
mic proteins that are bound to the cell wall through as yet undefined mechanisms17. Members of this group are 
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tissue adhesins, toxins and immune evasion factors. Since the functions of these proteins could be neutralized 
by effective antibody responses, they might be attractive targets for vaccination, provided that they are immuno-
genic. Recent reports have shown high immune responses against some members of this group, including IsaA, 
Efb and Atl18,19. Yet, in animal models it was shown that antibodies against these antigens provide only limited 
protection against challenges with S. aureus6,20.
Healthy immune-competent individuals display differing antibody responses to a vast array of S. aureus 
antigens, possibly reflecting their history of close encounters with multiple different S. aureus lineages21,22. 
Anti-staphylococcal antibody levels can increase strongly during bacteremia21,23, and it has been proposed 
that continuous exposure to different staphylococcal antigens might improve the effectiveness of the immune 
response22. Patients with the genetic blistering disease epidermolysis bullosa (EB) develop wounds that are highly 
susceptible to S. aureus colonization. Especially the chronic wounds of EB patients are heavily colonized with S. 
aureus and usually contain several different types of this pathogen24–27. This severe colonization of the wounds 
of EB patients is reflected in the very high anti-staphylococcal immunoglobulin G (IgG) levels in their plasma 
and blister fluid compared to the respective IgG levels in the plasma of healthy age-matched volunteers19,28. 
Importantly, also IgG4 responses against various S. aureus antigens were elevated in the plasma of EB patients, 
which is consistent with their long-term and/or repeated exposure to these antigens28. Remarkably, S. aureus bac-
teremia is infrequently observed in adult EB patients, suggesting that their anti-staphylococcal immune responses 
may be protective against invasive S. aureus infections19. Of note, in previous studies on the antibody responses of 
EB patients to S. aureus antigens, the non-covalently cell wall-bound proteins were underrepresented19,28.
The aim of the present exploratory study was to assess to what extent non-covalently cell wall-bound proteins 
of S. aureus are immunogenic and whether the respective IgG titers are elevated in plasma samples from EB 
patients. Based on a bioinformatics inventory and on data from our previous proteomics analyses of the S. aureus 
surfacome29, 10 non-covalently cell wall-bound proteins of S. aureus were selected, produced in Lactococcus lactis, 
and purified. The purified proteins were used to assess specific IgG levels in plasma samples from EB patients and 
healthy volunteers.
Materials and Methods
Bacterial strains, plasmids and growth conditions. Strains and plasmids used in this study are listed 
in Table 1. L. lactis strains were grown at 30 °C in M17 broth (Oxoid Limited, Hampshire, UK) supplemented with 
0.5% glucose (wt/vol) (GM17). When necessary the medium was supplemented with chloramphenicol (5 µg/ml) 
or erythromycin (5 µg/ml) for plasmid selection. S. aureus strains were grown at 37 °C, 250 rpm in Tryptone Soy 
Broth (TSB; Oxoid). E. coli strain MC1061 was grown at 37 °C, 250 rpm in Lysogeny broth (LB; Becton Dickinson, 
Breda, The Netherlands). When necessary, the medium was supplemented with ampicillin (100 µg/ml) for plas-
mid selection.
Isolation of S. aureus cell wall fragments. Cell wall fragments (CWFs) from S. aureus were isolated as 
described previously30. In short, S. aureus Newman cells were collected by centrifugation, glass-beads were added 
(0.1 µm beads, Biospec Products, Bartlesville, USA), and cells were disrupted for 2 min in a Precellys 24 homog-
enizer (Bertin Technologies, Saint Quentin en Yvelines Cedex, France). The resulting CWFs were collected by 
centrifugation and boiled at 96 °C for 10 min in 4% sodium dodecyl sulphate. This step was repeated twice. CWFs 
were subsequently washed six times with Phosphate Buffered Saline (PBS) and stored at −20 °C until further use.
Identification of non-covalently cell surface-bound proteins. Non-covalently cell wall-bound pro-
teins of S. aureus were identified by using the amino acid sequences of known domains for non-covalent cell 
wall-binding (i.e. PROSITE PS51780, PS51782, PS51781, PS51109) in BLAST searches against the sequenced 
S. aureus Newman strain. The actual identification of expressed non-covalently cell wall-bound proteins was 
accomplished as schematically represented in Fig. 1A. Upon overnight culturing in TSB, S. aureus Newman 
cells were incubated with 2 M potassium thiocyanate (KSCN) for 5 min leading to the release of non-covalently 
cell wall-bound proteins. Liberated non-covalently cell wall-bound proteins in the soluble fraction were either 
TCA-precipitated or dialyzed against PBS using a 3,500 Molecular weight cut-off (MWCO) membrane (Spectrum 
laboratories Inc. USA) as described before31. Secreted proteins present in S. aureus Newman growth medium 
fractions were also collected, either by TCA precipitation or dialysis of the spent growth medium against PBS. 
Dialyzed non-covalently cell wall-bound proteins were added to prepared S. aureus CWFs and incubated for 
5 min at 4 °C unless stated otherwise. CWFs containing non-covalently bound proteins were washed with PBS 
and non-covalently cell wall-bound proteins were released into the supernatant fraction by incubation with 2 M 
KSCN as described above. Released proteins were collected either by TCA precipitation or dialyzed overnight 
against demineralized water. Released proteins and cell pellets were separated by lithium dodecyl sulphate (LDS) 
- PAGE and the respective gels were stained with SimplyBlue SafeStain (Life Technologies, Grand Island, NY. 
USA). Protein bands were cut from the gels (Fig. 1B) and identified by Mass Spectrometry (MS) as described 
previously32.
Expression of non-covalently cell wall-bound proteins in L. lactis. PCR was performed with the 
Pwo DNA polymerase (Roche Diagnostics, Woerden, The Netherlands), using chromosomal DNA of S. aureus 
NCTC 8325 as template. Primers listed in Table 2 were designed to amplify gene sequences without the region 
coding for the natural secretion signals and with 5′ end extensions for ligase-independent cloning (LIC)33. Briefly, 
SwaI-digested pRE-USP plasmid and PCR fragments were treated with T4 DNA polymerase (20 °C, 20 min; 75 °C, 
20 min; Roche Diagnostics) before incubation for 5 min at room temperature (3:1 vector:insert). Z-Competent 
E. coli MC1061 cells (Zymo Research, Orange, CA, USA) were transformed with the plasmid:vector mixtures. 
Correct plasmids were confirmed by DNA sequencing (Eurofins DNA, Germany). For cloning in L. lactis, Vector 
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Backbone Exchange was performed by mixing ~300 ng of pERL vector with ~300 ng of the pRE-USP harboring 
the gene of interest, both digested with SfiI (New England Biolabs, Ipswich, UK). Ligation was performed using 
T4 DNA Ligase (New England Biolabs) and the resulting vector was introduced into electrocompetent L. lactis 
PA100134. For insertion of genes into plasmid pNG4210, primers (Table 2) were designed to amplify the respec-
tive sequences without the region coding for the natural secretion signals and with 5′ end extensions encoding 
BamHI (forward) or NotI (reverse) restriction sites. Briefly, digested PCR products and linearized plasmid were 
separated by agarose gel electrophoresis, and selected DNA fragments were gel-extracted and purified. Ligation 
of digested plasmid and PCR fragments was performed using T4 DNA ligase and the resulting plasmid was 
introduced into electrocompetent L. lactis PA1001 as described before35. For the expression of cloned genes, L. 
lactis cultures were induced in the exponential phase of growth (0.5 O.D. at 600 nm) by the addition of nisin (final 
concentration 3 ng/ml, Sigma-Aldrich, St. Luis, MO). After 4 h or overnight culturing, the cells were separated 
from the growth medium by centrifugation. Proteins in the nisin-induced growth medium fractions were precip-
itated with TCA (10% W/V) and resuspended in LDS gel loading buffer (Life Technologies). Cells in LDS sample 
buffer were disrupted with 0.1 µm glass beads in a Precellys 24 homogenizer. Both cellular and growth medium 
fractions were analyzed by LDS-PAGE (Life Technologies) and proteins were either visualized using protein stain-
ing with the SimplyBlue SafeStain (Life Technologies), or by blotting onto nitrocellulose membranes (Protan 
nitrocellulose transfer paper, Whatman, Germany) and subsequent immunodetection. For immunodetection, 
mouse anti-his tag primary antibodies (Life Technologies) and fluorescently labeled secondary antibodies (goat 
anti-mouse IRDye 800 CW, LI-COR Biosciences, Lincoln, NE. USA) were used. Antibody binding was visualized 
with an Odyssey infrared imaging system (LI-COR Biosciences).
Protein purification and activity measurements. When expressed proteins remained cell-associated, 
they were liberated from the cells either with 2 M KSCN or 6 M urea, as required. Next, the protein-containing 
soluble fractions were separated from the cell fraction by centrifugation. Subsequently, his-tagged proteins 
were purified from the respective supernatant fractions using the HisLink Protein Purification resin (Promega 
Corporation, Madison, WI. USA), in the absence or presence of either 2 M KSCN or 6 M urea. The HisLink bind-
ing and washing buffer was composed of 0.1 M HEPES 7.5 pH, 0.5 M NaCl and 10 mM imidazole. The elution 
buffers were essentially the same, but contained 200 mM or 400 mM imidazole. The IsaA and FtsL proteins were 
purified as described previously35,36.
Rebinding of isolated proteins to S. aureus cells. Overnight growth cultures of S. aureus Newman 
ΔspaΔsbi were resuspended to 1 optical density measured at 600 nm in 800 µl of PBS (pH 7) or 50 mM sodium 
acetate (pH 5) and incubated with 1–3 µg of histidine-tagged fusion proteins for 10 min. After incubation, cell 
pellets and supernatants were processed, and localization of tagged proteins was assessed by LDS-PAGE and 
Western blotting as described above.
Enzyme-linked immunosorbent assay (ELISA). Plasma samples were previously donated by patients 
with EB from the Dutch Epidermolysis Bullosa Registry (DEBR), and by healthy volunteers from the Netherlands. 
Strain or plasmid Relevant phenotype(s) or genotype(s) Source or reference
Strains
L. lactis PA1001 MG1363 pepN::nisRK, allows nisin-inducible expression, ΔacmA ΔhtrA 46
E. coli MC1061 araD139 Δ(araA-leu)7697 ΔlacX74 galK16 galE15(GalS) λ- e14- mcrA0 relA1 rpsL150(strR) spoT1 mcrB1 hsdR2 (Novagen, Madison, Wis)
S. aureus NCTC 8325 Propagating strain for typing phage 47 64
S. aureus Newman NCTC 8178 clinical isolate 65
S. aureus Newman Δspa Δsbi S. aureus Newman spa sbi mutant 31
Plasmids
pRE-USPnlic ampR; camR; pRExLIC fused with E. coli pBR322 replicon 33
pERL eryR; pERL fused with pSH71 replicon 33
pNG4210 camR pNG400 derivative, containing BamHI/EcoRI-XbaI/NotI cloning sites, his6 followed by a Stop codon 35
pNZ:LIC:efb Fusion of pRE-USPnlic with pERL containing efb (SAOUHSC_01114, aa 30–165) This study
pNZ:LIC:eap Fusion of pRE-USPnlic with pERL containing eap (SAOUHSC_02161, aa 31–584) This study
pNZ:LIC:sle1 Fusion of pRE-USPnlic with pERL containing sle1 (SAOUHSC_00427, aa 26–334) This study
pNZ:LIC:sa0710 Fusion of pRE-USPnlic with pERL containing sa0710 (SAOUHSC_00773, aa 25–279) This study
pNZ:LIC:atl1 Fusion of pRE-USPnlic with pERL containing atl1 (SAOUHSC_00994, aa 199–775) This study
pNZ:LIC:atl2 Fusion of pRE-USPnlic with pERL containing atl2 (SAOUHSC_00994, aa 776–1256) This study
pNG4210:lukG pNG4210 containing lukG with C-terminal his6 (SAOUHSC_02241, aa 30–338) This study
pNG4210:lukH pNG4210 containing lukH with C-terminal his6 (SAOUHSC_02243, aa 33–351) This study
pNG4210:ssaA2 pNG4210 containing ssaA2 with C-terminal his6 (SAOUHSC_02571, aa 28–267) This study
pNG4210:emp pNG4210 containing emp with C-terminal his6 (SAOUHSC_00816, aa 27–340) This study
pNG4210:ftsL pNG4210 containing ftsL with C-terminal his6 (USA300HOU_1120, aa 66–133) 35
Table 1. Strains and plasmids used in this study. Aa, amino acid residue; ampR, ampicillin resistance gene; 
camR, chloramphenicol resistance gene; eryR, erythromycin resistance gene; PnisA, nisin-inducible promoter; 
usp45ss, signal sequence of usp45.
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Figure 1. Identification of non-covalently cell wall-bound S. aureus proteins. (A) Schematic representation of 
the experimental set-up for identification of non-covalently cell wall-bound proteins. S. aureus cells were first 
separated from the growth medium by centrifugation (spin). Pelleted S. aureus cells were treated with KSCN 
to release the non-covalently cell wall-bound proteins. KSCN-extracted proteins were re-bound to cell wall 
fragments (CWF) and, subsequently, released again by KSCN incubation. Upon centrifugation, the resulting 
pellet and supernatant fractions were analyzed by LDS-PAGE (B). Upon Simply Blue safe staining of the gel, 
protein bands were excised and identified by MS as indicated.





















Table 2. Primer sequences used in this study. Underlined are the LIC cloning sequences/restriction sites.
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The EB patients included six patients with junctional EB (EB01, EB02, EB09, EB15, EB53, EB60), one patient with 
EB simplex (EB11), and one patient with dystrophic EB (EB51)19. ELISA plates were coated overnight at 4 °C 
with histidine-tagged fusion proteins (100ng/well) diluted in carbonate coating buffer (50 mM sodium carbonate, 
pH 9.6)6. Subsequently, the plates were blocked with PBS containing 5% skim milk. Patient and healthy control 
plasma samples were processed as previously described19. Serial dilutions of plasma (1000- to 2,000,000-fold) 
were prepared in PBS-Tween 20/5% skim milk. Specific anti-human IgG secondary antibodies coupled to horse-
radish peroxidase (dilution 1:8,000; Southern Biotechnology, Birmingham, AL) were used according to the man-
ufacturer’s recommendations. Horseradish peroxidase activity was quantified by measuring the hydrolysis of the 
substrate (O-Phenylenediamine, Sigma-Aldrich) at OD492 in a plate reader (Biotek Powerwave XS2, USA). The 
raw ELISA data are provided in Supplementary Information Table 1. Titers were calculated in arbitrary units 
(AU) through extrapolation using linear regression for data points from known dilutions giving OD492 values 
between 0.1 and 1.0. All calculated R2 linear regression values (Pearson product moment correlation coefficient) 
were above 0.98. IgG titers in plasma samples of EB patients were averaged and normalized by adjusting the 
averaged IgG titers in the control plasma samples of healthy volunteers to a single arbitrary level (AU = 10) and 
adjusting accordingly the averages for the EB patient samples. In brief, obtained EB and control averages were 
multiplied by a numeric factor that resulted in the average of all controls equal to 10 AU. After plotting normal-
ized values, the differences in the average IgG levels measured for plasma samples from EB patients and healthy 
control individuals were compared for the different analyzed proteins. Statistical significance of the ELISA data 
was tested with a Mann-Whitney U test for two independent samples (Supplementary Information Table 1).
Ethics statements. Blood donations from EB patients were collected with approval of the medical eth-
ics committee of the University Medical Center Groningen (approval no. NL27471,042,09). The Independent 
Ethics Committee of the Foundation ‘Evaluation of Ethics in Biomedical Research’ (Assen, the Netherlands), 
approved the protocol for blood donations from healthy volunteers, which is registered by QPS Groningen (code 
04132-CS011). Blood donations were obtained after written informed consent from all eight EB patients and the 
six healthy volunteers included in this study, and adhering to the Helsinki Guidelines19.
Results and Discussion
Selection of non-covalently cell wall-bound proteins. To pinpoint a panel of non-covalently cell wall-
bound proteins of S. aureus, we performed an extensive bioinformatics analysis using the genome sequence of S. 
aureus strain Newman and, in addition, we surveyed the results of our previous analysis of the cell surface pro-
teome of this S. aureus strain29. The results are summarized in Table 3. Specifically, the bioinformatics approach 
identified several SERAMS, in particular the extracellular adhesive protein Eap, the extracellular matrix protein 
Emp, the extracellular fibrinogen-binding protein Efb, and coagulase37. Furthermore, we retrieved all known S. 
aureus Newman proteins containing the conserved cell wall-binding domains LysM (PROSITE: PS51782)38,39, 
GW (PROSITE: PS51780)40, SH3B (PROSITE: PS51781)39,41 and G5 (PROSITE: PS51109)42. Except for the ami-
dase from phage phiNM2 and the transmembrane protein EbpS, all other identified proteins carried a predicted 
signal peptide for export from the cytoplasm (indicated as S in Table 3). Of note, Eap, Atl, IsaA, SsaA2, Sle1, 
LukG and LukH have also previously been identified as non-covalently cell wall-bound proteins16,29,43,44. Further, 
Sle1 was shown to be localized in the vicinity of the S. aureus cross-wall43,45, while Atl was found to be preferably 
bound to the septal region44.
To detect the actually produced non-covalently cell wall-bound proteins of S. aureus Newman and to ensure 
that the identified proteins do indeed behave as non-covalently cell wall-bound proteins, we extracted these 
proteins with the chaotrope KSCN from the staphylococcal cells, reattached them to isolated S. aureus CWFs, 
and re-extracted the proteins with KSCN (schematically represented in Fig. 1A). The proteins thus obtained 
were separated by LDS-PAGE. Eight dominant bands were detected, excised from the gel and identified by MS 
(Fig. 1B). The identifiers and characteristics of the identified proteins are summarized in Table 3. In this respect, 
it is noteworthy that our unpublished proteomics data indicate that only about 16% of the KSCN-extractable 
proteins are specifically cell wall-bound proteins.
For our further studies on human antibody responses against non-covalently cell wall-bound proteins of S. 
aureus, we made a selection of 10 representative proteins. The inclusion criteria for these 10 proteins were identi-
fication by bioinformatics and/or biochemical analysis. Exclusion criteria were a lack of identification in previous 
biochemical or proteomics analyses29, the absence of a predicted signal peptide, the presence of an LPxTG motif 
for covalent cell wall binding, and known IgG-binding properties that would interfere with our further analyses. 
The domain structure of the selected proteins, highlighting domains potentially involved in cell wall binding, is 
represented in Fig. 2. It should be noted that Atl is synthesized in a pre-pro-form which, upon export, is cleaved 
into two moieties with an amidase domain (here termed Atl1) and a glucosamidase domain (here termed Atl2). 
Accordingly, the Atl2 moiety of Atl does not have its own signal peptide for export from the cytoplasm.
Cloning, production and isolation of non-covalently cell wall-bound proteins in L. lactis. Genes 
for the selected non-covalently cell wall-bound proteins of S. aureus were cloned into nisin-inducible expression 
vectors and introduced into L. lactis strain PA1001 for expression. In the case of Atl, the Atl1 and Atl2 moieties 
were expressed separately, each being secreted with the lactococcal Usp45 signal peptide. Of note, the L. lactis 
PA1001 strain lacks the genes for the major extracellular protease HtrA and the autolysin AcmA, which min-
imizes proteolysis and cell lysis, respectively36,46. Next, expression of the cloned genes was induced with nisin 
and the subcellular localization of the respective S. aureus proteins was determined. To this end, cells were sep-
arated from the growth medium by centrifugation and the respective fractions were analyzed by LDS-PAGE 
and Western blotting using anti-His6 antibodies. As expected, all proteins were largely cell wall-bound (data not 
shown). By incubation of the cells with 2 M KSCN (Efb, Eap and Atl1) or 6 M urea (all seven other proteins), the 
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expressed proteins were released, consistent with disruption of their non-covalent interactions with the cell wall. 
Upon centrifugation, the released proteins were purified from the resulting supernatant fractions using Ni-NTA 
agarose beads, and their potential to re-bind to cells of S. aureus Newman Δspa Δsbi was confirmed (Fig. 3; data 
not shown for IsaA). Notably, Efb did not re-bind to S. aureus cells under the standard assay conditions (pH 
7), but its binding to the cells could be demonstrated at a lowered pH of 5 (Fig. 3). Altogether, these findings 
imply that the purified proteins have retained their cell wall-binding capabilities. Of note, the cell wall binding of 
SA0710 had not been experimentally verified so far, despite the fact that this protein has a LysM domain.
Human IgG responses against non-covalently cell wall-bound proteins of S. aureus. To assess 
whether EB patients and healthy volunteers mount immune responses against the selected non-covalently cell 
wall-bound proteins of S. aureus, we applied an ELISA approach. The membrane protein FtsL was included in 
this analysis as a control, because it is surface-exposed, but not bound to the cell wall29. As shown in Fig. 4A 
and Supplementary Information Table 1, all investigated human plasma samples contained IgGs against all 
Uniprot ID Gene names AA Se Protein name
Proteins with known conserved non covalently cell wall binding domains
LysM (PS51782)a
A6QH29 NWMN_1389 ebpS 486 Elastin-binding protein EbpS
A0A0H3K686 NWMN_0055 spa 520 S Immunoglobulin G binding protein A
A0A0H3K6S5 NWMN_0724 SA0710c 279 S Uncharacterized protein
A0A0H3K7F5 NWMN_0634 265 S Secretory antigen SsaA-like protein
A0A0H3KAZ4 NWMN_0429 sle1d 334 S N-acetylmuramoyl-L-alanine amidase AAA
A0A0H3KG37 NWMN_1157 lytN 383 S Cell-wall hydrolase LytN
GW (PS51780)a
A0A0H3K7X7 NWMN_0922 atl 1256 S Bifunctional autolysin
SH3B (PS51781)a
A0A0H3K875 NWMN_1039 481 Phage amidase [Bacteriophage phiNM2]
A0A0H3K8J7 NWMN_1534 291 S Probable cell wall amidase LytH
G5 (PS51109)a
A0A0H3KAI3 NWMN_2392 1501 S Uncharacterized protein
Identified by surfacome profiling
A0A0H3K7X7 NWMN_0922 atl 1256 S Bifunctional autolysin
A6QIG7 NWMN_1877 chp 149 S Chemotaxis inhibitory protein precursor
A0A0H3KA75 NWMN_0166 coa 636 S Coagulase
A6QF98 NWMN_0758 empd 340 S Extracellular matrix protein-binding protein emp precursor
A0A0H3KF27 NWMN_2399 fnbA 741 S Fibronectin binding protein A
A0A0H3K6R0 NWMN_0687 646 S Lipoteichoic acid synthase
A6QK59 NWMN_2469 isaA 233 S Probable transglycosylase IsaA precursor
A6QJQ7 NWMN_2317 sbi 436 S Immunoglobulin-binding protein sbi precursor
A0A0H3KCA1 NWMN_1066 109 S Uncharacterized protein Ehp
A0A0H3K6X4 NWMN_0362 203 S Uncharacterized protein
A0A0H3KET4 NWMN_0585 168 S Uncharacterized protein
A0A0H3K7N7 NWMN_0757 508 S Secreted von Willebrand factor-binding protein
A0A0H3KEG7 NWMN_2199 ssaA2d 267 S Secretory antigen SsaA
LDS-PAGE: Gel band MS
1b A6QIG2 NWMN_1872 eapd 584 S 65 kDa membrane protein precursor
A6QDC3 NWMN_0083 deoB 392 Phosphopentomutase
2 A6QG68 NWMN_1078 argF 333 Ornithine carbamoyltransferase
3 A6QIG2 NWMN_1872 eapd 584 S 65 kDa membrane protein precursor
4 A6QJQ7 NWMN_2317 sbi 436 S Immunoglobulin-binding protein Sbi precursor
5 A0A0H3KHT5 NWMN_1928 lukHd 351 S Leukocidin/hemolysin toxin family S subunit
6A6QF98 NWMN_0758 empd 340 S Extracellular matrix protein-binding protein Emp precursor
  A0A0H3K9N1 NWMN_1927 lukGd 338 S Leukocidin/hemolysin toxin family F subunit
7A0A0H3K5Z1 NWMN_0249 held 296 S 5′-nucleotidase, lipoprotein e(P4) family protein
  A0A0H3KIY0 NWMN_2444 85 Uncharacterized protein
8A6QG59 NWMN_1069 efbd 165 S Fibrinogen-binding protein precursor
Table 3. Identified non covalently cell surface-bound proteins. aPROSITE ID of Motif; bExtracted band number 
from LDS-PAGE; cGene locus of NWMN_0724 homolog in S. aureus N315, used instead of gene name; dGene 
name of homologous protein if none was found in the Uniprot record; Se Secretion signal predicted by SignalP 
and/or according to Uniprot.
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investigated proteins. Importantly, the levels of IgGs against non-covalently cell wall-bound proteins in plasma 
samples from EB patients were, on average, about 10-fold higher than those from healthy carriers. In this 
respect, the largest differences were observed for Eap, Atl2 and IsaA, and the smallest for Sle1 and Emp. Only, 
the FtsL-specific IgG levels in plasma samples from EB patients and healthy volunteers did not differ significantly 
(Fig. 4A). In this respect, it should be noted that for many, but not all, S. aureus antigens elevated IgG levels were 
previously observed in plasma from EB patients19,28. For example, no significant differences in IgG levels of EB 
patients and healthy volunteers were previously observed for the ClfA, ClfB and IsdH proteins bound to the 
staphylococcal cell wall.
We further inspected the overall IgG responses to all non-covalently cell wall-bound proteins per plasma 
sample, excluding FtsL. As shown in Fig. 4B, the normalized average IgG levels against the eleven remaining S. 
aureus antigens were higher for the eight plasma samples from EB patients than for the six healthy volunteers. 
Further, the carriage of multiple S. aureus strains by EB patients correlated with higher normalized average IgG 
levels (Fig. 4B). Thus, the highest normalized average IgG levels were observed for patients EB01 and EB51 who, 
respectively, were previously shown to carry 7 and 4 different S. aureus types at 3 time points of sampling19,28.
During S. aureus colonization and invasion, immune-competent individuals may rapidly mount antibody 
responses to a large panel of antigens. The antibody response profiles of individuals usually reflects the history 
of previous encounters with S. aureus22. Accordingly, they may change after every new encounter21, which could 
explain the strong variations in the profiles observed for different individuals28,47,48. Importantly, this was previ-
ously shown to even be the case upon controlled nasal inoculation of healthy human volunteers with S. aureus49.
In previous studies, we have reported that patients with EB develop wounds that are highly susceptible 
to S. aureus colonization19,24–26. Accordingly, it was shown that these patients mounted significantly higher 
immune responses against S. aureus antigens than healthy carriers19,28. In these studies, compared to healthy 
control individuals, elevated IgG levels were observed in plasmas of EB patients for three out of eleven tested 
cell wall-associated antigens (i.e. Efb, IsaA and IsdA), and for seven out of seventeen tested secreted antigens. 
Minor differences were observed for IgG responses against secreted superantigens19. In the present exploratory 
study, we show that EB patients carry significantly increased IgG levels against all eleven tested antigens that are 
non-covalently bound to the S. aureus cell wall, including Efb and IsaA. This novel observation highlights the 
Figure 2. Motif composition of non-covalently cell wall-bound proteins of S. aureus. The proteins 
shown are: the extracellular adherence protein Eap (SAOUHSC_02161); the bifunctional autolysin Atl 
(SAOUHSC_00994), of which the Atl1 (N-acetylmuramoyl-L-alanine amidase) and Atl2 (Endo-beta-
N-acetylglucosaminidase) domains were separately expressed; the CHAP and LysM domain-containing 
protein SA0710 (SAOUHSC_00773); the N-acetylmuramoyl-L-alanine amidase Sle1 (SAOUHSC_00427); 
the staphylococcal secretory antigen SsaA2 (SAOUHSC_02571); the gamma-hemolysin subunit B LukG 
(SAOUHSC_02241); the leukocidin LukH (SAOUHSC_02243); the probable transglycosylase IsaA 
(SA2356); the fibrinogen-binding protein Efb (SAOUHSC_01114); and the extracellular matrix protein-
binding protein Emp (SAOUHSC_00816). Sig, signal peptide; MAP, MAP repeat profile (PROSITE: 
PS51223); amidase, N-acetylmuramoyl-L-alanine amidase (Pfam: PF01510); glucosaminidase, endo-beta-N-
acetylglucosaminidase (Pfam: PF01832); GW, GW domain profile (PROSITE: PS51780); LysM, LysM domain 
profile (PROSITE:PS51782); CHAP, CHAP domain profile (PROSITE: PS50911); Leuk, Leukocidin/Hemolysin 
toxin family (Pfam: PF07968); NCD, N-terminal conserved domain; SLT, Transglycosylase SLT domain (Pfam: 
PF01464); Efb_c, extracellular fibrinogen binding protein C terminal (Pfam: PF12199); Fg, fibrinogen-binding 
motifs63. The green line represents amino acid residues selected for cloning and expression.
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strong immunogenicity of these antigens compared to other staphylococcal antigens that are covalently bound 
to the cell wall or secreted into the host environment. When IgG levels were compared for EB patients carrying 
multiple S. aureus types versus EB patients carrying only one S. aureus type, significant differences were observed 
for 4 out of 10 tested antigens, again including Efb and IsaA19. This general difference upon colonization with 
multiple S. aureus types was also observed in the present study, supporting the view that patients exposed to dif-
ferent S. aureus types are challenged with more staphylococcal antigens than patients carrying only one S. aureus 
type. Another novel finding is that EB patients showed a much larger variation in IgG levels against S. aureus 
antigens than healthy carrier controls. For example, the level of IgG against LukG in EB patient 02 was lower than 
the respective IgG levels in four of the healthy control individuals, whereas EB patient 53 showed the highest of 
all presently recorded IgG levels against LukG. Additionally, the comparison of plasma samples from EB patients 
and healthy control individuals revealed no significantly different IgG levels for other surface-exposed proteins 
of S. aureus, like FtsL. Thus, while it has been previously shown that EB patients have in general higher levels of 
antibodies against S. aureus antigens, our present study shows that (i) not all surface-exposed S. aureus proteins 
will elicit a similar antibody response in each EB patient, and that (ii) different EB patients similarly exposed to 
S. aureus may generate highly diverse patterns of antibody responses against particular S. aureus antigens. This 
relates most likely to their S. aureus contact history, which was previously shown to be variable over time19,24,26.
The species S. aureus is known to display high genomic plasticity. Although, the genes for some virulence 
factors are (almost) invariantly (Efb, Eap, Emp, IsaA) or frequently (Atl, LukG, LukH, SsaA2, Sle1) present in S. 
aureus isolates, their amino acid sequence identity and expression levels can show substantial inter-strain varia-
tions13,17,21,29,50–52. This diversity could be a determinant for variations in the host immune responses to S. aureus. 
Our results with Eap and Efb, which present large inter-lineage amino acid sequence variation51, showed a highly 
variable immune response in IgG titers in EB patients compared to healthy carriers. Interestingly, previous stud-
ies on different (not EB-related) patient cohorts showed either lower levels of anti-Eap and Efb antibodies in 
patients48,53,54 or, on the contrary, higher levels in infected patients than in healthy S. aureus carriers23,47,55,56. 
Nonetheless, consistently higher IgG titers against Atl14 and IsaA19 in sera of S. aureus-infected or colonized 
patients have been previously reported, which is in agreement with our own results.
In the context of our present study, it is noteworthy that except for very severe cases, patients with EB appear 
to suffer infrequently from invasive staphylococcal disease, especially if one considers their high rates of coloniza-
tion with S. aureus28. This has led to the proposal that the elevated levels of anti-staphylococcal IgGs could poten-
tially be protective. Importantly, none of the patients who participated in this and our previous studies was treated 
for S. aureus bacteremia in the 5 years prior to donating the investigated plasma samples. Additional support 
for the idea that high anti-staphylococcal IgG levels in EB patients could be protective comes from studies with 
monoclonal antibodies against IsaA, showing protection against S. aureus infections in murine S. aureus infec-
tion models6,7,57. At present, it is not clear whether these findings for anti-IsaA antibodies can be extrapolated to 
other non-covalently cell wall-bound proteins. This idea is tempting in view of the present results, but it has to be 
noted that vaccination studies in murine models with an octa-valent vaccine, including Atl and IsaA, did not lead 
to protection against S. aureus challenges18. Yet, immune responses directed against other presently investigated 
antigens could be beneficial, not only by promoting opsonophagocytosis, but also by interfering with the biolog-
ical activity of the different antigens as was recently shown for monoclonal antibodies against the staphylococcal 
complement inhibitor SCIN58. Clearly, potentially beneficial effects of using non-covalently cell surface-bound 
proteins as antigens for vaccination need to be thoroughly validated in immunization experiments. This is impor-
tant, because strong immune responses against S. aureus antigens may not be (fully) protective. This is under-
scored by the observation that S. aureus carriers producing antibodies that neutralize superantigens can still 
develop sepsis, although they do have an improved prognosis59. Also, in animal experiments high antibody titers 
Figure 3. Binding of purified non-covalently cell wall-bound proteins to S. aureus cells. Non-covalently cell 
wall-bound proteins were expressed in L. lactis and their binding to whole cells of S. aureus was assessed upon 
incubation at pH 7, or pH 5 in the case of Efb as indicated. Please note that the different groupings of blots 
(marked by boxes) were cropped per investigated protein from different parts of the same Western blot, or from 
different Western blots that were similarly processed and scanned. P, cell pellet fraction; S, supernatant fraction.
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against S. aureus antigens, such as IsaA, are not necessarily protective against infections by this pathogen18,60. 
In this context, it is noteworthy that Hawkins et al. showed that natural exposure of humans to S. aureus elic-
ited a strong antibody response against ClfA, but this response did not prevent the ClfA-mediated binding of S. 
aureus cells to fibrinogen, the natural ligand of ClfA61. In contrast, immunization with a ClfA-containing vaccine 
induced functional antibodies that prevented S. aureus from binding to fibrinogen. Another recent observation 
that encourages further research towards the development of an anti-staphylococcal vaccine was reported by 
Stentzel et al., who showed that immunoglobulin replacement therapy in STAT3 hyper-IgE syndrome patients 
with low S. aureus-specific serum IgG levels did not only increase the S. aureus-specific IgG levels, but also 
resulted in an attenuated clinical course of disease62.
Conclusion
In the present study, we assessed the immunogenicity of ten non-covalently cell surface-bound proteins of S. 
aureus, using plasma samples from patients with EB and healthy volunteers. Surface-exposed and secreted 
proteins of S. aureus have previously been studied as potential vaccine targets9,10. However, while most studies 
focused on covalently cell wall-bound proteins, the less-studied non-covalently cell wall-bound proteins could 
also be promising vaccine targets16. Therefore, we applied a combined bioinformatics and biochemical approach 
to select ten non-covalently cell wall-bound proteins of S. aureus for further analyses. These included Eap, Efb, 
EMP, IsaA, LukG, LukH, SA0710, Sle1 and SsaA2, as well as two separated domains of Atl. These potential anti-
gens were expressed in L. lactis, purified and tested for antigenicity using human plasma samples. Remarkably, 
our present results show that the high exposure of EB patients to S. aureus was mirrored by significantly elevated 
IgG levels against all tested non-covalently cell wall-bound antigens. This is a novel finding, which suggests that 
these antigens on the cell surface of S. aureus are prime targets for the human immune system.
Figure 4. Binding of human IgGs to purified non-covalently cell wall-bound S. aureus proteins. Levels of 
IgGs specific for purified cell wall-bound S. aureus proteins were compared by ELISA using plasma samples of 
patients with EB (red bullets) or healthy S. aureus carriers (blue bullets). (A) Normalized IgG titers in different 
plasma samples plotted per purified S. aureus antigen. (B) Normalized IgG titers in different plasma samples 
plotted per EB patient and healthy carrier. In brief, obtained EB and control averages were multiplied by a 
numeric factor that resulted in the average of all controls equal to 10 AU. After plotting normalized values, 
the differences in the average IgG levels measured for plasma samples from EB patients and healthy control 
individuals were compared for the different analyzed proteins (isolates/tests). Per patient, the number of S. 
aureus types identified per number of sampling time points are indicated in parentheses19,24,26. Sa, S. aureus.
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